Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca to ally with MRC Technology on disease research

AstraZeneca to ally with MRC Technology on disease research

7th July 2010

AstraZeneca is to collaborate with the Medical Research Council’s commercialisation company MRC Technology on a joint project into innovative new medicines.

Under the terms of the agreement, AstraZeneca and MRC Technology are to share access to each other’s library of compounds, a move which will give the two organisations access to a combined total of around 150,000 agents.

These compounds are to be screened to gauge their potential efficacy against a variety of biological targets and disease areas, including cancer, neuroscience and infection, before being developed into commercial medical products.

It is hoped that the collaboration will allow the organisations to maximise the potential of their compound libraries and lead to breakthroughs that will benefit patients.

Alan Lamont, director of science and technology alliances at AstraZeneca, said: “This deal represents a novel and creative way in which we can generate more value from one of our most significant assets.”

This comes after AstraZeneca recently announced that it will be providing Medicines for Malaria Venture with access to 50,000 of its compounds in an effort to discover new malaria treatments.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.